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Purpose: To measure levels of high-mobility group box −1 (HMGB1) and soluble receptor for advanced glycation end
products (sRAGE) in the vitreous fluid from patients with proliferative diabetic retinopathy (PDR) and to correlate their
levels with clinical disease activity and the levels of the inflammatory biomarkers monocyte chemoattractant protein-1
(MCP-1), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-1β (IL-1β), and granulocyte macrophage
colony-stimulating factor (GM-CSF). In addition, we examined the expression of HMGB1 in the retinas of diabetic mice.
Methods: Vitreous samples from 29 PDR and 17 nondiabetic patients were studied by enzyme-linked immunosorbent
assay. Retinas of mice were examined by immunofluorescence analysis and western blotting.
Results: HMGB1 was detected in all vitreous samples and sRAGE was detected in 5 PDR samples. IL-1β was detected
in 3PDR samples and GM-CSF was not detected. Mean HMGB1 levels in PDR with active neovascularization were
twofold and threefold higher than that in inactive PDR and nondiabetic patients, respectively. Mean HMGB1 levels in
PDR patients with hemorrhage were significantly higher than those in PDR patients without hemorrhage and nondiabetic
patients (p=0.0111). There were significant correlations between levels of HMGB1 and levels of MCP-1 (r=0.333,
p=0.025) and sICAM-1 (r=0.548, p<0.001). HMGB1 expression was also upregulated in the retinas of diabetic mice.
Conclusions: Subclinical chronic inflammation might contribute to the progression of PDR.
Proliferative  diabetic  retinopathy  (PDR)  is  a  serious
complication  of  diabetes  mellitus  and  is  characterized  by
epiretinal  outgrowth  of  fibrovascular  membranes  at  the
vitreoretinal interface. Formation of fibrovascular tissue often
leads to severe visual loss due to vitreous hemorrhage and/or
tractional retinal detachment. Strong evidence indicates that
chronic  low-grade  inflammation  is  implicated  in  the
pathogenesis of diabetic retinopathy. Diabetic retinal vascular
leakage, capillary nonperfusion, and endothelial cell damage
are associated with leukocyte recruitment and adhesion to the
retinal vasculature, findings that correlate with the increased
expression  of  retinal  intercellular  adhesion  molecule-1
(ICAM-1) and the leukocyte integrin CD18. Inhibition of
ICAM-1 activity in animals deficient in the gene encoding for
ICAM-1 or by a neutralizing antibody suppresses both retinal
leukostasis and vascular leakage [1,2]. The causal relationship
between  inflammation  and  angiogenesis  is  now  widely
accepted  [3].  An  emerging  issue  in  diabetic  retinopathy
research  is  the  focus  on  the  mechanistic  link  between
activation  of  subclinical  inflammation  and  angiogenesis.
Several  studies  reported  elevated  levels  of  biomarkers  of
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inflammation  and  endothelial  dysfunction,  including
monocyte chemoattractant protein-1 (MCP-1), interferon-γ-
inducible  protein  of  10  kDa,  interleukin-6  (IL-6),  tumor
necrosis factor-α, soluble intercellular adhesion molecule-1
(sICAM-1), and soluble vascular cell adhesion molecule-1
(sVCAM-1)  in  the  vitreous  from  patients  with  PDR  and
diabetic macular edema [4-8].
High-mobility  group  box  −1  protein  (HMGB1)  is  a
nonhistone,  DNA-binding,  nuclear  protein  that  is  highly
conserved  during  evolution.  It  stabilizes  nucleosome
formation  and  facilitates  gene  transcription.  Necrotic  cell
death can result in passive leakage of HMGB1 from the cell
as the protein is then no longer bound to DNA. In addition,
HMGB1  can  be  actively  secreted  by  different  cell  types,
including  activated  monocytes  and  macrophages,  mature
dendritic  cells,  natural  killer  cells,  and  endothelial  cells.
Extracellular  HMGB1  functions  as  a  proinflammatory
cytokine [3,9-11] and exhibits angiogenic effects [12-15].
HMGB1 signals through the receptor for advanced glycation
end  products  (RAGE),  a  member  of  the  immunoglobulin
superfamily  of  receptors,  leading  to  activation  of  the
transcription factor nuclear factor κB (NF-κB), and induces
the expression of various leukocyte adhesion molecules and
pro-inflammatory  cytokines  and  chemokines  [3,9-11].
Several  studies  demonstrated  that  RAGE  mediates  the
inflammatory  [9-11]  and  angiogenic  [12,16]  activities  of
HMGB1.
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1829Soluble  RAGE  (sRAGE),  a  truncated  form  of  the
receptor,  is  composed  of  the  extracellular  ligand-binding
domain lacking the cytosolic and transmembrane domains
(i.e., the part that transfers the signal to the cell). This soluble
form of the receptor has the same ligand-binding capacity and
competes with cell-bound RAGE for ligand binding, therefore
functioning as a “decoy” abrogating cellular activation since
the cell-surface receptor remains unoccupied. Indeed, it has
been demonstrated in several experimental animal models that
treatment with sRAGE prevents cell-bound RAGE signaling
[17].
The  aim  of  this  study  was  to  measure  the  levels  of
HMGB1 and sRAGE in the vitreous fluid from patients with
PDR and to correlate their levels with clinical disease activity
and  the  levels  of  other  biomarkers  of  inflammation  and
endothelial dysfunction, including MCP-1, sICAM-1, IL-1β,
and granulocyte macrophage colony-stimulating factor (GM-
CSF). In addition, we investigated the expression of HMGB1
in the retinas of diabetic mice.
METHODS
Vitreous  samples:  Undiluted  vitreous  fluid  samples  (0.3–
0.6 ml) were obtained from 29 patients with PDR during pars
plana  vitrectomy.  All  surgeries  were  performed  at  King
Abdulaziz University Hospital, Riyadh, Saudi Arabia. The
indications for vitrectomy were traction retinal detachment
and/or nonclearing vitreous hemorrhage. The clinical ocular
findings were graded at the time of vitrectomy for the presence
or absence of visible new vessels on the retina or optic disc.
Patients with active PDR were graded as such on the basis of
visible patent new vessels on the retina or optic disc. Their
absence indicated involuted (inactive) PDR. Active PDR was
present in 15 patients, and inactive PDR was present in 14
patients.  Traction  retinal  detachment  was  present  in  12
patients and vitreous hemorrhage in 20 patients. The diabetic
patients were 24 males and five females, whose ages ranged
from 30 to 70 years with a mean of 46.9±9.9 years. The
duration of diabetes ranged from 7 to 32 years with a mean of
16.4±5.6 years. Twenty-three patients had insulin-dependent
diabetes mellitus, and six patients had noninsulin-dependent
diabetes mellitus. At presentation, the fasting blood glucose
was uncontrolled in 24 patients and controlled in five patients.
Twenty patients were receiving treatment for hypertension,
and two patients had diabetic neophropathy. Lipid profile
assays showed elevated serum levels in nine patients. The
control group consisted of 17 patients who had undergone
vitrectomy  for  the  treatment  of  rhegmatogenous  retinal
detachment  (RD)  with  no  proliferative  vitreoretinopathy.
Controls were free from systemic disease. Vitreous samples
were  collected  undiluted  by  manual  suction  to  a  syringe
through the aspiratin line of vitrectomy, before opening the
infusion line. The samples were centrifuged (5,000× g for 10
min, 4 °C), and the supernatants were aliquoted and frozen at
−80 °C until assay. The study was conducted according to the
tenets of the Declaration of Helsinki, and informed consent
was obtained from all patients. The study was approved by the
Research Center, College of Medicine, King Saud University.
Animals:  All  procedures  with  animals  were  performed  in
accordance with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research and were approved by the
institutional Animal Care and Use Committee, Georgia Health
Sciences University (GHSU). C57Bl/6J mice (The Jackson
Laboratory, Bar Harbor, ME), weighing 25 to 30 g at the
beginning of the study, were used. Diabetes was induced by
intravenous injection of streptozotocin (STZ; Sigma-Aldrich,
St. Louis, MO; 55 mg/kg, dissolved in 0.1 M sodium citrate
buffer [pH 4.5]). Mice were considered diabetic if their blood
glucose was greater than 250 mg/dl. After 8 weeks the animals
were sacrificed by carbon dioxide (CO2) inhalation and the
retinas of one eye of each mouse were removed, snap frozen
in liquid nitrogen, and stored at −80 °C to be analyzed by
western blotting. The other eye was enucleated and embedded
in  optimal  cutting  temperature  compound  (Electron
Microscopy Sciences, Hatfield, PA) to prepare frozen sections
(10 μm).
Enzyme-linked  immunosorbent  assay  kits:  Enzyme-linked
immunosorbent  assay  (ELISA)  kits  for  human  sRAGE
(Quantikine Human Soluble Receptor for Advance Glycation
end Product, Cat No: DRG00; R&D systems, Minneapolis,
MN),  human  GM-CSF  (Quantikine  Human  Granulocyte
Macrophage Colony Stimulating factor, Cat No: DGM00),
human IL-1β (Quantikine Human Interleukin 1 beta, Cat No:
DLB50),  human  MCP-1  (Quantikine  Human  Monocyte
Chemotactic Protein 1, Cat No: SCP00), and human sICAM
(Quantikine  Human  soluble  Intercellular  Adhesion
Molecules, Cat No: DCD540) were purchased from R&D
Systems. An ELISA kit for HMGB-1 was purchased from IBL
International  GMBH  (Hamburg,  Germany).  The  detection
limit  for  each  ELISA  kit  for  sRAGE,  GM-CSF,  IL-1β,
MCP-1, sICAM-1, and HMGB-1 is 4.12 pg/ml, 3 pg/ml, 1 pg/
ml,  5  pg/ml,  96  pg/ml,  and  200  pg/ml,  respectively.  The
ELISA plate readings were done using FLUOstar Omega-
Miroplate reader from BMG Labtech (Offenburg, Germany).
Preparation of buffers and reagent was done using ultrapure
deionized water from Milli-Q Integral 10 system, Millipore
(Billerica, MA).
Preparation of standards: To prepare the series of standards,
we followed the serial dilution methods. For each ELISA kit,
the  undiluted  standard  serves  as  the  highest  standard  and
calibrator diluents serve as the zero standard. Depending upon
the  detection  range  for  each  ELISA  kit,  the  supernatant
vitreous obtained was used either directly or diluted with
calibrator diluents supplied with the ELISA kit.
Measurement  of  human  soluble  receptor  for  advanced
glycation  end  products,  granulocyte  macrophage  colony-
stimulating  factor,  interleukin-1β,  and  monocyte
chemoattractant protein-1: Quantification of human sRAGE,
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1830GM-CSF,  IL-1β,  and  MCP-1  in  the  vitreous  fluid  was
determined using ELISA kits according to the manufacturer’s
instruction (R&D Systems). For the measurement of sRAGE
and GM-CSF in vitreous, an amount of 100 µl of assay diluent
RD1–60 and RD1–6 (R&D Systems), respectively, and 50 µl
of either the standard controls for sRAGE and 100 µl standard
control for GM-CSF or an undiluted vitreous ﬂuid sample for
sRAGE and GM-CSF were added to each well of the ELISA
plate. Similarly for the measurement of IL-1β and MCP-1 in
vitreous, an amount of 50 µl of assay diluent RD1–83 (R&D
Systems)  and  200  µl  of  either  the  standard  controls  for
IL-1β and MCP-1 or twofold-diluted vitreous for IL-1β and
20-fold-diluted vitreous for MCP-1 were added to each well
of the ELISA plate. The assay was performed in duplicate for
each standard or vitreous sample. At room temperature, the
ELISA plate was incubated on a shaker for 2 h and was washed
as per the kit instruction, using a 1× diluted washing solution
(R&D Systems). An amount of 200 µl of polyclonal antibody
against sRAGE, GM-CSF, IL-1β, and MCP-1 conjugated to
horseradish peroxidase (R&D Systems) was added to each
well of the ELISA plate, incubated for 2 h on the shaker at
room temperature, and washed using the 1× diluted washing
solution.  Immediately  after  washing,  a  200-µl  substrate
solution,  prepared  using  a  1:1  ratio  of  color  reagent  A
(hydrogen  peroxide;  R&D  Systems)  and  color  reagent  B
(tetramethylbenzidine as a chromogen; R&D Systems), was
added to each well and kept for another 30 min of incubation
at room temperature and protected from light. The reaction
was completed with the addition of 50 µl of stop solution (2
N sulfuric acid; R&D Systems) to each well of the ELISA
plate in the same order as the substrate solution had been
added, and the optical density (OD) was immediately read at
450  nm,  using  a  microplate  reader  with  a  wavelength
correction of 540 nm. Using the four parameter fit logistic (4-
PL) curve equation for making the standards curve, the actual
concentration for each sample was calculated. For the vitreous
fluid  that  had  been  diluted,  the  correction  read  from  the
standard curve obtained using 4-PL was multiplied by the
dilution factors to get the actual reading for each sample.
Measurement  of  human  soluble  intercellular  adhesion
molecule-1:  The  quantification  of  human  sICAM  in  the
vitreous fluid was determined using ELISA kits according to
the  manufacturer’s  instruction  (R&D  Systems).  First  an
amount of 100 µl of monoclonal antibody against sICAM
conjugated to horseradish peroxidase was added to each well,
followed by the immediate addition of 100 µl of either the
standard controls or threefold diluted vitreous fluid sample to
each well of the ELISA plate. The assay was performed in
duplicate  for  each  standard  or  vitreous  sample.  At  room
temperature, the ELISA plate was incubated on a shaker for
1.5 h and was washed four times using the 1× diluted washing
solution (R&D Systems). Using the 4-PL curve equation for
making the standards curve, the actual concentration for each
sample was calculated. For calculating the actual reading for
each  sample,  the  correction  read  from  the  standard  curve
obtained using 4-PL was multiplied by the dilution factors (3
times). For measuring sICAM, we diluted the vitreous fluid 3
times with diluent buffer that was supplied with the kit. To get
the  actual  concentration  of  sICAM  we  multiplied  the
calculated reading with the dilution factor 3.
Measurement of human high-mobility group box−1: With
little modification, the quantification of human HMGB1 in the
vitreous fluid was determined using ELISA kits according to
the manufacturer’s instruction (IBL International GMBH).
For measuring within the high sensitivity range, 65 µl of
diluents buffer (Dilbuf, IBL International) was added to each
microtiter plate followed, by the addition of 35 µl of standard,
positive control, and vitreous fluid in the respective microtiter
plate. After a brief shaking of the plate for 30 s, the plate was
covered with adhesive foil and incubated for 22 h at 37 °C.
Using the wash solution (Hamburg, Germany) diluted 5 times
with deionized water, each well was washed 5 times, and
100  µl  polyclonal  HMGB1  antibody  conjugated  to
horseradish peroxidase was added to each well, which was
then incubated for another 2 h at room temperature. After
washing five times, 100 µl of substrate solution (color reagent
A,  tetramethylbenzidine  and  color  reagent  B,  0.005  M
hydrogen peroxide) was added to each well (prepared 5 min
before its addition), and wells were then kept for 30 min at
room  temperature.  The  reaction  was  completed  by  the
addition of 100 µl of stop solution (0.35 M H2SO4), and the
OD was measured at 450 nm using a microplate reader with
a wavelength correction of 620 nm. Using the 4-PL curve for
making  the  standards  curve,  the  actual  concentration  was
calculated for each sample and the controls.
Immunofluorescence analysis: The retinal sections were fixed
using 4% formalin, blocked with serum-free protein blocker
(Dako, Carpinteria, CA) at 25 °C in Coplin jars for 1 h, and
then incubated with primary antibody over night at 4 °C. We
performed double labeling for rabbit polyclonal anti-HMGB1
(1:100; Abcam, Cambridge, MA) and isolectin B4 (Vector
Laboratories,  Burlingame,  CA)  as  the  vascular  marker
(15 μg/ml). After overnight incubation we washed the slides
three times with PBS (1x Phosphate buffer saline, Cat. No.
70011, Invitrogen, New York, NY)-Triton X-100 (0.2%) and
then used Oregon Green antirabbit IgG (Molecular Probes;
Invitrogen Corporation, Carlsbad, CA) and Texas Red Avidin
D (Vector Laboratories) for HMGB1 and isolectin labeling,
respectively. Sections were rinsed and washed three times (5
min each)and then mounted on slides by using Vectashield
mounting  medium  with  4’,6-diamidino-2-phenylindole
(DAPI)  as  a  nuclear  marker  (Vector  Laboratories),  and
examined by confocal microscopy (Carl Ziess NTS, LLC,
Peabody, MA).
Western-blot  analysis:  Retinas  were  homogenized  in  a
modified  radioimmunoprecipitation  lysis  (RIPA)  buffer
(20 mM Tris-HCl; pH 7.4), 2.5 mM EDTA, 50 mM NaF,
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183110 mM Na4P2O7, 1% Triton X-100, 0.1% sodium dodecyl
sulfate  [SDS],  1%  sodium  deoxycholate,  and  1  mM
phenylmethyl sulfonyl fluoride). The lysate was centrifuged
at 14,000× g for 10 min at 4 °C, and the supernatant was
collected. Equal amounts of protein were separated on 10%
SDS-polyacrylamide  gels.  Proteins  were  transferred  onto
polyvinylidene difluoride membranes and blocked with 5%
nonfat dry milk in Tris-buffered saline with 0.1% Tween-20
(TBS-T) for 1 h at room temperature. The membranes were
incubated  overnight  with  rabbit  polyclonal  anti-HMGB1
(1:1,000;  Abcam,  Cambridge,  MA).  After  overnight
incubation with primary antibody, membranes were washed
three times with TBS-T (10 min each) and then incubated with
antirabbit  secondary  horseradish  peroxidase-conjugated
antibody  at  room  temperature  for  1  h.  Membranes  were
washed again three times with TBS-T (10 min each) and then
the  bands  were  visualized  on  a  high-performance
chemiluminescence film (GE Healthcare, Pittsburgh, PA) by
using enhanced chemiluminescence plus (GE Healthcare) and
quantified by densitometric analysis using Image processing
and Analysis in Java (Image-J software, Open Source, Public
Domain). As a control, the blots were stripped and detected
with  a  mouse  monoclonal  anti-β-actin  antibody  (1:5,000;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA). All data
from the three independent experiments were expressed as a
ratio to OD.
Statistical  analysis:  The  Mann–Whitney  test  was  used  to
compare  means  from  two  independent  groups.  Pearson
correlation  coefficients  were  computed  to  investigate
correlations between variables. One-way ANOVA (ANOVA)
and  post-ANOVA  pairwise  comparisons  of  means  were
conducted using the Kruskal–Wallis test. For three groups, the
critical Z value for post-ANOVA pairwise mean comparisons
was Z=2.39 at a 5% level of significance. A p value less than
0.05  indicated  statistical  significance.  Stepwise  logistic
regression  analysis  was  conducted  to  identify  the
inflammatory biomarkers that had a strong relationship with
the activity of PDR. Statistical Package for the Social Sciences
Version  12  (SPSS  12.0),  for  Windows  XP  (SPSS  Inc.,
Chicago, IL), and programs 3S and LR from Bio-Medical
Data  Processing  Version  2007  (BMDP  2007)  Statistical
Software (Cork Technology Pack, Model Farm Road, Cord,
Ireland) were used for the statistical analyses.
RESULTS
Inflammatory biomarker levels in vitreous samples: HMGB1,
MCP-1, and sICAM-1 were detected in all vitreous samples
from patients with PDR and nondiabetic patients. sRAGE was
detected in only five (17.2%) vitreous samples from patients
with PDR at low levels (15.6, 45.8, 129.9, 29.5, and 69.1 pg/
ml,  respectively).  None  of  the  vitreous  samples  from
nondiabetic  patients  showed  detectable  levels  of  sRAGE.
IL-1β was detected in only three (10.3%) vitreous samples
from patients with PDR at low levels (7.6, 5.9, and 6.3 pg/ml,
respectively). None of the vitreous samples from nondiabetic
patients showed detectable levels of IL-1β. GM-CSF was not
detected  in  vitreous  samples  from  patients  with  PDR  or
nondiabetic patients.
When patients with PDR were divided into those with
active neovascularization and those with quiescent disease,
the mean levels of HMGB1 in vitreous samples from patients
with active PDR were approximately twofold higher than in
inactive PDR patients and threefold higher than in nondiabetic
patients. Likewise, the mean levels of MPC-1 and sICAM-1
were approximately twofold higher in active PDR patients
than in inactive PDR patients (Table 1). Comparison of the
mean levels of inflammatory biomarkers among active PDR
patients, inactive PDR patients, and nondiabetic patients was
conducted using the Kruskal–Wallis test, and the results are
shown in Table 1. Mean levels differed significantly between
the  three  groups  for  MCP-1  (p=0.007)  and  sICAM-1
(p<0.001)  but  not  for  HMGB1.  Post-ANOVA  pairwise
comparisons of means indicated that mean MCP-1 levels were
significantly higher in patients with active PDR than the mean
levels in patients with inactive PDR (Z=2.91) and nondiabetic
patients (Z=2.43). For sICAM-1, the mean levels for patients
with  active  PDR  and  patients  with  inactive  PDR  were
significantly  higher  than  the  mean  levels  in  nondiabetic
patients (Z=4.44, Z=2.93, respectively).
When patients with PDR were divided into those with or
without  hemorrhage,  the  mean  levels  of  inflammatory
biomarkers differed significantly between PDR patients with
hemorrhage,  PDR  patients  without  hemorrhage,  and
nondiabetic patients for HMGB1 (p=0.0111) and sICAM-1
(p<0.001)  but  not  for  MCP-1  (Table  2).  Post-ANOVA
pairwise comparisons of means highlighted that for HMGB1
TABLE 1. COMPARISONS OF MEAN INFLAMMATORY BIOMARKER LEVELS IN RELATION TO TYPE OF PROLIFERATIVE DIABETIC RETINOPATHY (PDR).
Disease group HMGB1 (ng/ml) MCP-1 (ng/ml) sICAM-1 (ng/ml)
Active PDR (n=15) 6.34±9.2 3.77±2.9 29.8±21.9
Inactive PDR (n=14) 3.06±3.1 1.93±1.5 15.45±5.6
Controls (n=17) 2.31±2.0 2.42±2.1 9.93±4.6
ANOVA p-value 0.257 0.007* <0.001*
        *Statistically significant at 5% level. Abbreviations: HMGB1 represents high-mobility group box  −1; MCP-1 represents
        monocyte chemoattractant protein-1; sICAM-1 represents soluble intercellular adhesion molecule-1
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1832the mean levels were significantly higher for PDR patients
with hemorrhage than for PDR patients without hemorrhage
(Z=2.82). For sICAM-1, the mean levels for PDR patients
with or without hemorrhage were significantly higher than for
nondiabetic patients (Z=4.42, Z=2.49, respectively).
There were significant correlations between the vitreous
fluid levels of HMGB1 and the levels of MCP-1 (r=0.333,
p=0.025) and sICAM-1 (r=0.548, p<0.001). There was also a
significant correlation between the vitreous fluid levels of
MCP-1 and sICAM-1 (r=0.511, p<0.001) Stepwise logistic
regression  analysis  was  conducted  to  identify  the
inflammatory  biomarkers  that  tended  to  relate  most
importantly to the activity of PDR and the presence of vitreous
hemorrhage. High levels of sICAM-1 in the vitreous fluid
were significantly associated with active neovascularization
(odds ratio=1.14; 95% confidence interval [CI]=1.04–1.26).
High levels of HMGB1 were associated with the presence of
vitreous hemorrhage (odds ratio=6.55; 95% CI=0.616–69.6),
but the association was not statistically significant.
When vitreous samples from patients with PDR were
divided into those with or without detectable levels of sRAGE,
mean levels of MCP-1 and sICAM-1 were significantly higher
in  vitreous  samples  with  detectable  levels  of  sRAGE
compared  to  those  without  detectable  levels  of  sRAGE
(p<0.001 for both comparisons). The mean HMGB1 levels
were higher in vitreous samples with detectable levels of
sRAGE compared with those without detectable levels of
sRAGE; the difference was marginally statistically significant
(p=0.0532; Table 3).
There were no significant relationships between vitreous
levels of biomarkers of inflammation and systemic disease
variables (Table 4).
Effect of diabetes on retinal expression of high-mobility group
box −1 in experimental mice: Our previous studies reported
early  inflammatory  response  in  retina  of  STZ-induced
diabetic mice, characterized by increased leukocyte adhesion
and vascular permeability [18]. We tested whether this early
inflammatory response is associated with any change in the
retinal levels of HMGB1. Our western blotting demonstrated
a significant increase in HMGB1 expression in the retina of
diabetic mice compared to the control (p=0.007; Figure 1).
Using  immunofluorescence  we  noticed  that  HMGB-1  is
highly expressed in ganglion cells, inner nuclear layers, and
retinal vasculatures (Figure 2).
DISCUSSION
In the present study we investigated the correlations between
the levels of HMGB1 and sRAGE and the levels of other
inflammatory biomarkers in vitreous samples from patients
with PDR. In addition, we investigated the association of the
inflammatory biomarkers in vitreous samples with the activity
of PDR and the presence of vitreous hemorrhage. We also
investigated  the  expression  of  HMGB1  in  the  retinas  of
diabetic mice. The main findings were as follows: (1) Vitreous
levels  of  HMGB1,  MCP-1,  and  sICAM-1  were  higher  in
patients with active PDR compared with patients with inactive
PDR and nondiabetic patients. (2) Vitreous levels of HMGB1
and sICAM-1 were higher in PDR patients with hemorrhage
compared  with  PDR  patients  without  hemorrhage  and
TABLE 2. COMPARISONS OF MEAN INFLAMMATORY BIOMARKER LEVELS IN PROLIFERATIVE DIABETIC RETINOPATHY (PDR) PATIENTS WITH OR
WITHOUT HEMORRHAGE
Disease Group HMGB1 (ng/ml) MCP-1 (ng/ml) sICAM-1 (ng/ml)
PDR with hemorrhage (n=20) 6.18±8.1 2.91±1.9 25.53±19.3
PDR without hemorrhage (n=9) 1.60±1.8 2.83±3.6 17.05±11.8
Controls (n=17) 2.31±2.0 2.42±2.1 9.93±4.6
ANOVA p-value 0.0111* 0.1709 <0.001*
        *Statistically significant at 5% level. Abbreviations: HMGB1 represents high-mobility group box  −1; MCP-1 represents
        monocyte chemoattractant protein-1; sICAM-1 represents soluble intercellular adhesion molecule-1.
TABLE 3. COMPARISONS OF MEAN INFLAMMATORY BIOMARKER LEVELS IN PROLIFERATIVE DIABETIC RETINOPATHY VITREOUS SAMPLES
WITH OR WITHOUT DETECTABLE SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (SRAGE)
  sRAGE detected  
Inflammatory biomarker Yes No Mann–Whitney test p-value
HMGB1 (ng/ml) 11.9±14.7 3.3±3.2 0.0532
MCP-1 (ng/ml) 6.9+3.8 2.0±0.9 <0.001*
sICAM-1 (ng/ml) 51.1±23.6 15.9±7.9 <0.001*
         *Statistically significant at 5% level. Abbreviations: HMGB1 represents high-mobility group box  −1; MCP-1 represents
         monocyte chemoattractant protein-1; sICAM-1 represents soluble intercellular adhesion molecule-1.
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1833nondiabetic patients. (3) Among the inflammatory factors that
we investigated, sICAM-1 had a stronger influence on the
activity  of  PDR  than  the  other  factors.  (4)  There  were
significant  correlations  between  the  vitreous  levels  of
HMGB1,  MCP-1,  and  sICAM-1.  (5)  Levels  of  HMGB1,
MCP-1, and sICAM-1 were higher in vitreous samples with
detectable levels of sRAGE compared with vitreous samples
without detectable levels of sRAGE. These findings suggest
that HMGB1, MCP-1, and sICAM-1 play an important role
in  the  progression  of  PDR.  In  addition,  we  demonstrated
upregulation of HMGB1 expression in the retinas of diabetic
mice.
In this study, HMGB1 and MCP-1 were detected in all
vitreous samples from patients with rhegmatogenous retinal
TABLE 4. RELATIONSHIP BETWEEN INFLAMMATORY BIOMARKER LEVELS AND SYSTEMIC DISEASE VARIABLES
Variable HMGB1 (ng/ml) MCP-1 (ng/ml) sICAM-1 (ng/ml)
Type of diabetes
Insulin-dependent 5.02±7.9 2.76±2.6 21.0±14.6
Non-insulin-dependent 3.04±2.0 3.17±2.1 19.5±8.2
p-value 0.834 0.294 0.816
Fasting blood glucose
Controlled 2.92± 2.6 3.29±2.5 26.1±12.9
Uncontrolled 4.96±7.7 2.76±2.6 19.9±13.7
p-value 0.896 0.431 0.131
Hyperlipidemia
Yes 3.51±2.2 4.34±4.2 30.3±13.7
No 6.04±10.4 2.78±2.3 19.9±15.7
p-value 0.708 0.399 0.092
Hypertension
Yes 5.17±8.5 3.03±3.0 21.8±14.5
No 3.62±3.1 2.42±0.6 18.5±11.9
p-value 0.605 0.21 0.363
        Abbreviations:  HMGB1  represents  high  mobility  group  box−1;  MCP-1  represents  monocyte  chemoattractant  protein-1;
        sICAM-1 represents soluble intercellular adhesion molecule-1.
Figure 1. Western-blotting analysis of
high-mobility group box −1 (HMGB1)
in mouse retina. There is a significant
increase in the expression of HMGB1 in
the  retinas  of  diabetic  mice  (D)
compared to the nondiabetic control (C).
OD is optical density
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1834detachment (RD). Our results are consistent with previous
reports  that  demonstrated  elevated  levels  of  HMGB1  and
MCP-1 in the vitreous samples from patients with RD [5,19].
In vivo studies showed that induction of retinal detachment in
rats  induced  upregulation  of  HMGB1  in  both  the
photoreceptors  and  the  other  retinal  cells  and  release  of
HMGB1 in the subretinal space [19]. These findings suggest
that HMGB1 could be released not only in the subretinal space
but also in the vitreous cavity after RD-induced photoreceptor
degeneration.  In  the  present  study,  PDR  eyes  with  active
neovascularization had a twofold increase in the vitreous level
of HMGB1 when compared with those with quiescent disease
and a threefold increase in the vitreous level of HMGB1 when
compared with those with RD. These results are in agreement
with a previous report in which we demonstrated that HMGB1
and RAGE were expressed by vascular endothelial cells and
stromal cells in PDR fibrovascular epiretinal membranes and
that there were significant correlations between the level of
vascularization  in  PDR  epiretinal  membranes  and  the
expression of HMGB1 and RAGE. Moreover, the expression
of HMGB1 and RAGE in membranes from patients with
active neovascularization was significantly higher than that in
membranes from patients with inactive PDR [20]. In addition,
we demonstrated that HMGB1 levels in vitreous samples of
PDR patients with hemorrhage were significantly higher than
in PDR patients without hemorrhage. Taken together, these
findings suggest a role for the HMGB1/RAGE signaling axis
in  the  progression  of  PDR.  Recently,  HMGB1  has  been
recognized as an angiogenic cytokine [12-15]. Several studies
demonstrated that RAGE mediates the angiogenic activities
of HMGB1 [12,16]. Another interesting role of HMGB1 in
neovascularization  is  its  ability  to  attract  endothelial
progenitor cells to sites of tissue injury and tumors to improve
neovascularization in a RAGE-dependent manner [14]. In the
present study we also demonstrated that HMGB1 expression
was upregulated in the retinas of diabetic mice. This finding
can  be  correlated  with  our  previous  report  of  increased
ICAM-1  expression,  leukocyte  adhesion,  and  vascular
permeability  in  retinas  of  diabetic  mice  [18].  Similarly,
increased vascular [21] and renal [22] HMGB1 expression
was recently demonstrated in diabetic animals. In addition,
hyperglycemia-induced reactive oxygen species production
increases the expression of HMGB1 and RAGE in endothelial
cells [23]. Arimura et al. [19] showed that oxidative stress
augmented  HMGB1  in  the  nucleus  and  induced  massive
release  of  HMGB1  from  cultured  retinal  cells  to  the  cell
supernatants.
Sustained  pro-inflammatory  responses  in  diabetic
retinopathy are often associated with angiogenesis [1,2,4,24].
The  causal  relationship  between  inflammation  and
angiogenesis is now widely accepted [3]. The current data
show a significant correlation between the vitreous levels of
HMGB1  and  that  of  the  other  inflammatory  biomarkers
MCP-1 and sICAM-1. Previous studies reported that HMGB1
activates human endothelial cells to upregulate the expression
of RAGE and ICAM-1, to release MCP-1, and to increase
Figure 2. Immunolocalization of high-mobility group box −1 (HMGB1) in control (upper row of panels) and diabetic (lower row of panels)
retinas. Immunofluorescence using isolectin B4 as a vascular marker (red), a nuclear marker 4’,6-diamidino 2-phenylindole (DAPI), and
HMGB1 antibody showed increased expression of HMGB1 in diabetic retina in comparison to the control. HMGB1 is localized mainly in
ganglion cells (GC), inner nuclear layer (INL), and retinal vasculatures (arrows). Abbreviations: IPL represents inner plexiform layer; OPL
represents outer plexiform layer; ONL represents outer nuclear layer.
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1835neutrophil adhesion. This pro-inflammatory phenotype was
mediated  by  the  activation  of  NF-κB  and  was  RAGE
dependent as it was inhibited by antibodies directed toward
RAGE [9-11].
Our results of increased levels of MCP-1 and sICAM-1
in the vitreous samples from patients with PDR are consistent
with  previous  reports  [4-6].  Furthermore,  we  found  that
MCP-1 and sICAM-1 levels in vitreous samples from active
PDR cases were significantly higher than in inactive PDR
cases. In a previous study we also demonstrated that MCP-1
protein  was  localized  in  vascular  endothelial  cells  and
myofibroblasts in PDR epiretinal membranes and that there
was  a  significant  correlation  between  the  level  of
vascularization  and  the  expression  of  MCP-1  in  PDR
epiretinal membranes [4]. Recently, MCP-1 and its regulation
by high glucose levels in vascular cells has been implicated
in the pathogenesis of the inflammatory process associated
with diabetes [25]. In addition, MCP-1 has been recognized
as an angiogenic chemokine [26,27]. In vivo angiogenesis
assays showed that MCP-1-induced angiogenesis is as potent
as that induced by vascular endothelial growth factor [26].
Elevated levels of sICAM-1 are thought to indicate a state
of  endothelial  activation  with  consequent  induction  of
immunological activity [28]. Several studies demonstrated
elevated plasma levels of sICAM-1 and other inflammatory
biomarkers  and  their  association  with  microvascular
complications  in  diabetic  patients  [29,30].  In  addition,
intensive therapy in patients with type 1 diabetes mellitus
reduced serum levels of sICAM-1 [31]. In the current study,
multivariate analysis demonstrated a significant association
between  active  PDR  and  high  levels  of  sICAM-1.  In
agreement with our findings, previous studies showed that
vitreous levels of sICAM-1 were significantly associated with
the severity of diabetic macular edema [7].
sRAGE, a truncated form of the receptor, binds ligands
with affinity equal to that of cellular RAGE. It therefore has
the ability to prevent RAGE signaling acting as a “decoy” by
binding ligands and preventing them from reaching the cell-
surface  RAGE.  In  vitro,  sRAGE  added  to  cultured  cells
blocked  the  effects  of  RAGE  ligands  on  expression  of
inflammatory markers, cellular migration and proliferation,
and cytotoxicity [17]. sRAGE has successfully been used in
a variety of animal disease models to antagonize RAGE-
mediated  pathologic  processes  [17,32].  Several  studies
showed that sRAGE might beneficially impact early vascular
and  neuronal  dysfunction  in  the  diabetic  retina.  Systemic
administration  of  sRAGE  inhibits  blood–retinal  barrier
breakdown, leukostasis, and expression of ICAM-1 in the
retina of diabetic animals [33]. In addition, attenuation of the
RAGE  axis  with  sRAGE  ameliorated  retinal  neuronal
dysfunction and reduced the development of capillary lesions
in a murine model of nonproliferative diabetic retinopathy
[34]. In the present study, the presence of detectable levels of
sRAGE was associated with increased levels of HMGB1,
MCP-1, and sICAM-1 in vitreous samples from patients with
PDR. These results suggest that elevated levels of sRAGE in
vitreous  from  patients  with  PDR  potentially  negatively
regulates  inflammation  and  that  sRAGE  is  secreted
extracellularly as a negative feedback mechanism to limit the
inflammation. Similarly, in rheumatoid arthritis patients with
erosive disease, there is a positive correlation between the
white cell count and synovial sRAGE levels [35]. In addition,
blood  sRAGE  levels  are  higher  in  systemic  lupus
erythematosus patients compared with controls. Compared
with quiescent systemic lupus erythematosus, blood sRAGE
levels are significantly increased during active disease [32].
It is, therefore, hypothesized that the association between
detection  of  sRAGE  and  elevated  levels  of  HMGB1  in
vitreous samples from patients with PDR is protective against
HMGB1-elicited cellular activation by complexing HMGB1
and promoting its clearance. On the other hand, in vitro studies
revealed that treatment of cells with HMGB1 increased the
formation of sRAGE released in the supernatants [32].
In  addition  to  its  role  in  mediating  amplification  of
inflammation and angiogenesis, several studies demonstrated
that extracellular HMGB1 can aggravate tissue damage in
neuronal tissues after ischemia. HMGB1 is released to the
extracellular space immediately after ischemic injury from
neurons, and it subsequently induces neurodegeneration in the
postischemic  brain  [36-38].  In  these  studies,  extracellular
HMGB1 plays a key role in the development of neuronal
injury through microglial activation [38] and induction of
apoptosis [39], excitatory amino acid release [40,41], and pro-
inflammatory mediators [41].
In conclusion, our findings suggest the presence of a pro-
inflammatory state in PDR as evidenced by increased levels
of HMGB1, MCP-1, and sICAM-1 in the vitreous. Activation
of subclinical chronic inflammation might contribute to the
pathogenesis and progression of PDR. Moreover, HMGB1
expression was enhanced in the retinas of diabetic mice.
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